Literature DB >> 16322602

A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality.

Vivian G Loo1, Louise Poirier, Mark A Miller, Matthew Oughton, Michael D Libman, Sophie Michaud, Anne-Marie Bourgault, Tuyen Nguyen, Charles Frenette, Mirabelle Kelly, Anne Vibien, Paul Brassard, Susan Fenn, Ken Dewar, Thomas J Hudson, Ruth Horn, Pierre René, Yury Monczak, André Dascal.   

Abstract

BACKGROUND: In March 2003, several hospitals in Quebec, Canada, noted a marked increase in the incidence of Clostridium difficile-associated diarrhea.
METHODS: In 2004 we conducted a prospective study at 12 Quebec hospitals to determine the incidence of nosocomial C. difficile-associated diarrhea and its complications and a case-control study to identify risk factors for the disease. Isolates of C. difficile were typed by pulsed-field gel electrophoresis and analyzed for binary toxin genes and partial deletions in the toxin A and B repressor gene tcdC. Antimicrobial susceptibility was evaluated in a subgroup of isolates.
RESULTS: A total of 1703 patients with 1719 episodes of nosocomial C. difficile-associated diarrhea were identified. The incidence was 22.5 per 1000 admissions. The 30-day attributable mortality rate was 6.9 percent. Case patients were more likely than matched controls to have received fluoroquinolones (odds ratio, 3.9; 95 percent confidence interval, 2.3 to 6.6) or cephalosporins (odds ratio, 3.8; 95 percent confidence interval, 2.2 to 6.6). A predominant strain, resistant to fluoroquinolones, was found in 129 of 157 isolates (82.2 percent), and the binary toxin genes and partial deletions in the tcdC gene were present in 132 isolates (84.1 percent).
CONCLUSIONS: A strain of C. difficile that was resistant to fluoroquinolones and had binary toxin and a partial deletion of the tcdC gene was responsible for this outbreak of C. difficile-associated diarrhea. Exposure to fluoroquinolones or cephalosporins was a risk factor. Copyright 2005 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322602     DOI: 10.1056/NEJMoa051639

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  617 in total

1.  Community-associated Clostridium difficile infection: experience of a veteran affairs medical center in southeastern USA.

Authors:  S Naggie; J Frederick; B C Pien; B A Miller; D T Provenzale; K C Goldberg; C W Woods
Journal:  Infection       Date:  2010-05-08       Impact factor: 3.553

Review 2.  Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review.

Authors:  Marwan S Abougergi; John H Kwon
Journal:  Dig Dis Sci       Date:  2010-10-06       Impact factor: 3.199

3.  Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency.

Authors:  J H Boone; M Goodykoontz; S J Rhodes; K Price; J Smith; K N Gearhart; R J Carman; T M Kerkering; T D Wilkins; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-14       Impact factor: 3.267

Review 4.  Clostridium difficile in the ICU: the struggle continues.

Authors:  Linda D Bobo; Erik R Dubberke; Marin Kollef
Journal:  Chest       Date:  2011-12       Impact factor: 9.410

5.  A multiplex, internally controlled real-time PCR assay for detection of toxigenic Clostridium difficile and identification of hypervirulent strain 027/ST-1.

Authors:  A M Hoegh; J B Nielsen; A Lester; A Friis-Møller; K Schønning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-09-22       Impact factor: 3.267

6.  Hospital-acquired Clostridium difficile infection: determinants for severe disease.

Authors:  J M Wenisch; D Schmid; H-W Kuo; E Simons; F Allerberger; V Michl; P Tesik; G Tucek; C Wenisch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-12-31       Impact factor: 3.267

7.  In vivo selection of moxifloxacin-resistant Clostridium difficile.

Authors:  Ana Mena; Elena Riera; Carla López-Causapé; Irene Weber; José L Pérez; Antonio Oliver
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

Review 8.  Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors:  Kathleen Mullane
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

9.  Comparison of a commercial real-time PCR assay for tcdB detection to a cell culture cytotoxicity assay and toxigenic culture for direct detection of toxin-producing Clostridium difficile in clinical samples.

Authors:  Paul D Stamper; Romina Alcabasa; Deborah Aird; Wisal Babiker; Jennifer Wehrlin; Ijeoma Ikpeama; Karen C Carroll
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

10.  Effective and reduced-cost modified selective medium for isolation of Clostridium difficile.

Authors:  Michelle M Nerandzic; Curtis J Donskey
Journal:  J Clin Microbiol       Date:  2008-12-10       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.